Global Monoclonal Antibodies

Monoclonal Antibodies Comprehensive Study by Application (Cancer, Rheumatoid arthritis, Multiple sclerosis, Cardiovascular disease, Systemic lupus erythematosus, Crohn's disease, Other), Drug Type (Abciximab, Adalimumab, Alefacept, Other), Productions (Vivo, Vitro), Formulation (Lyophilized powder for reconstitution, Solution for injection), Source (Fully human, Humanized, Chimeric, Other), End User (Hospitals, Speciality centers, Others) Players and Region - Global Market Outlook to 2026

Monoclonal Antibodies Market by XX Submarkets | Forecast Years 2021-2026  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Monoclonal Antibodies Market Scope
Antibodies, also known as immunoglobulins, are Y-shaped proteins that recognize and neutralize the antigens of invading microbes. The effectiveness of our immune system is determined by how quickly and effectively such antibodies are produced. However, antigen-antibody reactions can be beneficial or harmful. It is not always possible, however, to wait for the body's immune system to produce effective antibodies. As in the case of an epidemic or pandemic, the disease may spread quickly, seriously affecting one or more organs, and multiple lives may be lost. When people who were infected with a specific virus or bacteria did not develop severe symptoms, it indicates that their immune system produced antibodies that were effective in combating the microbe's antigens. Antibodies can be found in their bodies up to 5 or 7 months after infection. These antibodies can be injected into a patient's body if they are carefully extracted or harvested from their body and then replicated or 'cloned' in a laboratory. The patient's body now has the antibodies needed to combat the antigens of the invader. Monoclonal Antibodies, or MABs, are antibodies that have been cloned or duplicated. Unlike MABs, vaccines aim to stimulate the immune system to produce antibodies that are effective in combating the foreign antigen MAB is an inorganic approach, whereas vaccine is an organic one. Monoclonal antibodies are a type of protein that can bind to specific targets in the body, such as antigens on the surface of cancer cells. There are various types of monoclonal antibodies, and each monoclonal antibody is designed to bind to a single antigen. Many diseases, including some types of cancer, are being diagnosed and treated with monoclonal antibodies. They can be used alone or in conjunction with other agents to deliver drugs, toxins, or radioactive substances directly to cancer cells.

AttributesDetails
Study Period2016-2026
Base Year2020
UnitValue (USD Million)
Key Companies ProfiledNovartis AG (Switzerland), Pfizer, Inc. (United States), AstraZeneca (United Kingdom), GlaxoSmithKline plc (United Kingdom), Johnson & Johnson Services, Inc. (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Amgen, Inc. (United States), Merck & Co., Inc (United States), Daiichi Sankyo Company, Ltd. (Japan) and Novo Nordisk A/S (Denmark)
CAGR%


The market has seen a massive investment in R&D and product development which has driven the market growth. Massive investments and partnerships to establish a more significant product have helped to grab more markets for key players. The significant response shown in treatments of diseases like cancer has been driving the market. Hospitals have started preferring the treatment over others as this is cost-effective and reliable. This has made new entrances grab a good position in the market. Whereas the big players have tried to develop by mergers and acquisitions and investments in developing better technology to keep up with the competition and hold a higher position in the market. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Monoclonal Antibodies market throughout the predicted period.

Novartis AG (Switzerland), Pfizer, Inc. (United States), AstraZeneca (United Kingdom), GlaxoSmithKline plc (United Kingdom), Johnson & Johnson Services, Inc. (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Amgen, Inc. (United States), Merck & Co., Inc (United States), Daiichi Sankyo Company, Ltd. (Japan) and Novo Nordisk A/S (Denmark) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Abbott (United States), Eli Lilly (United States), Bayer AG (United States), Bristol Myers Squibb Co. (United States), Mylan N.V. (United States), Biogen Inc. (United States), Thermo Fisher Scientific, Inc. (United States) and Sanofi Genzyme (France).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Monoclonal Antibodies market by Type , by Application (Cancer, Rheumatoid arthritis, Multiple sclerosis, Cardiovascular disease, Systemic lupus erythematosus, Crohn's disease and Other) and Region with country level break-up.

On the basis of geography, the market of Monoclonal Antibodies has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2020.

Market Leaders and their expansionary development strategies
In January 2021 Novartis has signed a strategic collaboration agreement to in-license tislelizumab from BeiGene, Ltd. in major markets outside of China, accelerating the potential for Novartis to enter the large and growing checkpoint inhibitor field. Tislelizumab is an anti-PD-1 monoclonal antibody specifically designed to minimize binding to Fcγ R on macrophages.
In June 2022 Novartis announced results from the Phase III RATIONALE 306 trial showing tislelizumab plus chemotherapy significantly improved overall survival (OS) as a first-line treatment for adult patients with unresectable, locally advanced, or metastatic esophageal squamous cell carcinoma (ESCC), regardless of PD-L1 status. Tislelizumab plus chemotherapy demonstrated a median OS of 17.2 months (CI, 15.8-20.1 months) versus 10.6 months (CI, 9.3-12.1 months) in patients receiving chemotherapy plus placebo and reduced the risk of death by 34% (hazard ratio=0.66; CI, 0.54-0.80, p<0.0001).1 In collaboration with BeiGene, these data were presented today during a late-breaking oral session at the 2022 European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer (Abstract #LBA-1).
Since November 2020, the U.S. Food and Drug Administration (FDA) has issued several emergency use authorizations (EUAs) to permit the emergency use of investigational monoclonal antibody (mAb) therapies for the treatment of mild to moderate COVID-19 in adult and pediatric patients. Currently authorized mAbs are:, Bebtelovimab (Lilly) EUA issued Feb. 11, 20221 and Bebtelovimab is authorized for use in pediatric patients with positive results from direct SARS-CoV-2 viral testing and who are ages 12 to 17, weigh at least 40 kilograms, and are at high risk for progressing to severe COVID-19 and/or hospitalization. In addition, bebtelovimab is authorized only for people “for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate.”

Monoclonal Antibodies Market Dynamics:
AttributesDetails
Trends Influencing Market
  • The shift in Preference for Cost-Effective Treatments has Been Showing a Trending Impact on Monoclonal Antibodies Market.
Key Restraints
  • Alternative Treatment Methods.
Challenges
  • Poor Demand in Underdeveloped Economies.
Market Opportunities
  • Higher Investments and Strategic Partnerships for Further Research and Development by Leading Companies.
  • Positive Results of Implementation of Monoclonal Antibodies Treatment for Covid-19 has Opened Many Opportunities.


Key Target Audience
Pharmaceutical companies, New Entrants and Investors, Legalized Cannabis Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

Report Objectives / Segmentation Covered

By Application
  • Cancer
  • Rheumatoid arthritis
  • Multiple sclerosis
  • Cardiovascular disease
  • Systemic lupus erythematosus
  • Crohn's disease
  • Other
By Drug Type
  • Abciximab
  • Adalimumab
  • Alefacept
  • Other

By Productions
  • Vivo
  • Vitro

By Formulation
  • Lyophilized powder for reconstitution
  • Solution for injection

By Source
  • Fully human
  • Humanized
  • Chimeric
  • Other

By End User
  • Hospitals
  • Speciality centers
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The Monoclonal Antibodies Therapy Use in Cancer Treatment Has Been Driving the Market Growth.
    • 3.3. Market Challenges
      • 3.3.1. Poor Demand in Underdeveloped Economies.
    • 3.4. Market Trends
      • 3.4.1. The shift in Preference for Cost-Effective Treatments has Been Showing a Trending Impact on Monoclonal Antibodies Market.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Monoclonal Antibodies, by Application, Drug Type, Productions, Formulation, Source, End User and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Monoclonal Antibodies (Value)
      • 5.2.1. Global Monoclonal Antibodies by: Application (Value)
        • 5.2.1.1. Cancer
        • 5.2.1.2. Rheumatoid arthritis
        • 5.2.1.3. Multiple sclerosis
        • 5.2.1.4. Cardiovascular disease
        • 5.2.1.5. Systemic lupus erythematosus
        • 5.2.1.6. Crohn's disease
        • 5.2.1.7. Other
      • 5.2.2. Global Monoclonal Antibodies by: Drug Type (Value)
        • 5.2.2.1. Abciximab
        • 5.2.2.2. Adalimumab
        • 5.2.2.3. Alefacept
        • 5.2.2.4. Other
      • 5.2.3. Global Monoclonal Antibodies by: Productions (Value)
        • 5.2.3.1. Vivo
        • 5.2.3.2. Vitro
      • 5.2.4. Global Monoclonal Antibodies by: Formulation (Value)
        • 5.2.4.1. Lyophilized powder for reconstitution
        • 5.2.4.2. Solution for injection
      • 5.2.5. Global Monoclonal Antibodies by: Source (Value)
        • 5.2.5.1. Fully human
        • 5.2.5.2. Humanized
        • 5.2.5.3. Chimeric
        • 5.2.5.4. Other
      • 5.2.6. Global Monoclonal Antibodies by: End User (Value)
        • 5.2.6.1. Hospitals
        • 5.2.6.2. Speciality centers
        • 5.2.6.3. Others
      • 5.2.7. Global Monoclonal Antibodies Region
        • 5.2.7.1. South America
          • 5.2.7.1.1. Brazil
          • 5.2.7.1.2. Argentina
          • 5.2.7.1.3. Rest of South America
        • 5.2.7.2. Asia Pacific
          • 5.2.7.2.1. China
          • 5.2.7.2.2. Japan
          • 5.2.7.2.3. India
          • 5.2.7.2.4. South Korea
          • 5.2.7.2.5. Taiwan
          • 5.2.7.2.6. Australia
          • 5.2.7.2.7. Rest of Asia-Pacific
        • 5.2.7.3. Europe
          • 5.2.7.3.1. Germany
          • 5.2.7.3.2. France
          • 5.2.7.3.3. Italy
          • 5.2.7.3.4. United Kingdom
          • 5.2.7.3.5. Netherlands
          • 5.2.7.3.6. Rest of Europe
        • 5.2.7.4. MEA
          • 5.2.7.4.1. Middle East
          • 5.2.7.4.2. Africa
        • 5.2.7.5. North America
          • 5.2.7.5.1. United States
          • 5.2.7.5.2. Canada
          • 5.2.7.5.3. Mexico
  • 6. Monoclonal Antibodies: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novartis AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. AstraZeneca (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. GlaxoSmithKline plc (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Johnson & Johnson Services, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Amgen, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Merck & Co., Inc (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Daiichi Sankyo Company, Ltd. (Japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Novo Nordisk A/S (Denmark)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Monoclonal Antibodies Sale, by Application, Drug Type, Productions, Formulation, Source, End User and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Monoclonal Antibodies (Value)
      • 7.2.1. Global Monoclonal Antibodies by: Application (Value)
        • 7.2.1.1. Cancer
        • 7.2.1.2. Rheumatoid arthritis
        • 7.2.1.3. Multiple sclerosis
        • 7.2.1.4. Cardiovascular disease
        • 7.2.1.5. Systemic lupus erythematosus
        • 7.2.1.6. Crohn's disease
        • 7.2.1.7. Other
      • 7.2.2. Global Monoclonal Antibodies by: Drug Type (Value)
        • 7.2.2.1. Abciximab
        • 7.2.2.2. Adalimumab
        • 7.2.2.3. Alefacept
        • 7.2.2.4. Other
      • 7.2.3. Global Monoclonal Antibodies by: Productions (Value)
        • 7.2.3.1. Vivo
        • 7.2.3.2. Vitro
      • 7.2.4. Global Monoclonal Antibodies by: Formulation (Value)
        • 7.2.4.1. Lyophilized powder for reconstitution
        • 7.2.4.2. Solution for injection
      • 7.2.5. Global Monoclonal Antibodies by: Source (Value)
        • 7.2.5.1. Fully human
        • 7.2.5.2. Humanized
        • 7.2.5.3. Chimeric
        • 7.2.5.4. Other
      • 7.2.6. Global Monoclonal Antibodies by: End User (Value)
        • 7.2.6.1. Hospitals
        • 7.2.6.2. Speciality centers
        • 7.2.6.3. Others
      • 7.2.7. Global Monoclonal Antibodies Region
        • 7.2.7.1. South America
          • 7.2.7.1.1. Brazil
          • 7.2.7.1.2. Argentina
          • 7.2.7.1.3. Rest of South America
        • 7.2.7.2. Asia Pacific
          • 7.2.7.2.1. China
          • 7.2.7.2.2. Japan
          • 7.2.7.2.3. India
          • 7.2.7.2.4. South Korea
          • 7.2.7.2.5. Taiwan
          • 7.2.7.2.6. Australia
          • 7.2.7.2.7. Rest of Asia-Pacific
        • 7.2.7.3. Europe
          • 7.2.7.3.1. Germany
          • 7.2.7.3.2. France
          • 7.2.7.3.3. Italy
          • 7.2.7.3.4. United Kingdom
          • 7.2.7.3.5. Netherlands
          • 7.2.7.3.6. Rest of Europe
        • 7.2.7.4. MEA
          • 7.2.7.4.1. Middle East
          • 7.2.7.4.2. Africa
        • 7.2.7.5. North America
          • 7.2.7.5.1. United States
          • 7.2.7.5.2. Canada
          • 7.2.7.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Monoclonal Antibodies: by Application(USD Million)
  • Table 2. Monoclonal Antibodies Cancer , by Region USD Million (2015-2020)
  • Table 3. Monoclonal Antibodies Rheumatoid arthritis , by Region USD Million (2015-2020)
  • Table 4. Monoclonal Antibodies Multiple sclerosis , by Region USD Million (2015-2020)
  • Table 5. Monoclonal Antibodies Cardiovascular disease , by Region USD Million (2015-2020)
  • Table 6. Monoclonal Antibodies Systemic lupus erythematosus , by Region USD Million (2015-2020)
  • Table 7. Monoclonal Antibodies Crohn's disease , by Region USD Million (2015-2020)
  • Table 8. Monoclonal Antibodies Other , by Region USD Million (2015-2020)
  • Table 9. Monoclonal Antibodies: by Drug Type(USD Million)
  • Table 10. Monoclonal Antibodies Abciximab , by Region USD Million (2015-2020)
  • Table 11. Monoclonal Antibodies Adalimumab , by Region USD Million (2015-2020)
  • Table 12. Monoclonal Antibodies Alefacept , by Region USD Million (2015-2020)
  • Table 13. Monoclonal Antibodies Other , by Region USD Million (2015-2020)
  • Table 14. Monoclonal Antibodies: by Productions(USD Million)
  • Table 15. Monoclonal Antibodies Vivo , by Region USD Million (2015-2020)
  • Table 16. Monoclonal Antibodies Vitro , by Region USD Million (2015-2020)
  • Table 17. Monoclonal Antibodies: by Formulation(USD Million)
  • Table 18. Monoclonal Antibodies Lyophilized powder for reconstitution , by Region USD Million (2015-2020)
  • Table 19. Monoclonal Antibodies Solution for injection , by Region USD Million (2015-2020)
  • Table 20. Monoclonal Antibodies: by Source(USD Million)
  • Table 21. Monoclonal Antibodies Fully human , by Region USD Million (2015-2020)
  • Table 22. Monoclonal Antibodies Humanized , by Region USD Million (2015-2020)
  • Table 23. Monoclonal Antibodies Chimeric , by Region USD Million (2015-2020)
  • Table 24. Monoclonal Antibodies Other , by Region USD Million (2015-2020)
  • Table 25. Monoclonal Antibodies: by End User(USD Million)
  • Table 26. Monoclonal Antibodies Hospitals , by Region USD Million (2015-2020)
  • Table 27. Monoclonal Antibodies Speciality centers , by Region USD Million (2015-2020)
  • Table 28. Monoclonal Antibodies Others , by Region USD Million (2015-2020)
  • Table 29. South America Monoclonal Antibodies, by Country USD Million (2015-2020)
  • Table 30. South America Monoclonal Antibodies, by Application USD Million (2015-2020)
  • Table 31. South America Monoclonal Antibodies, by Drug Type USD Million (2015-2020)
  • Table 32. South America Monoclonal Antibodies, by Productions USD Million (2015-2020)
  • Table 33. South America Monoclonal Antibodies, by Formulation USD Million (2015-2020)
  • Table 34. South America Monoclonal Antibodies, by Source USD Million (2015-2020)
  • Table 35. South America Monoclonal Antibodies, by End User USD Million (2015-2020)
  • Table 36. Brazil Monoclonal Antibodies, by Application USD Million (2015-2020)
  • Table 37. Brazil Monoclonal Antibodies, by Drug Type USD Million (2015-2020)
  • Table 38. Brazil Monoclonal Antibodies, by Productions USD Million (2015-2020)
  • Table 39. Brazil Monoclonal Antibodies, by Formulation USD Million (2015-2020)
  • Table 40. Brazil Monoclonal Antibodies, by Source USD Million (2015-2020)
  • Table 41. Brazil Monoclonal Antibodies, by End User USD Million (2015-2020)
  • Table 42. Argentina Monoclonal Antibodies, by Application USD Million (2015-2020)
  • Table 43. Argentina Monoclonal Antibodies, by Drug Type USD Million (2015-2020)
  • Table 44. Argentina Monoclonal Antibodies, by Productions USD Million (2015-2020)
  • Table 45. Argentina Monoclonal Antibodies, by Formulation USD Million (2015-2020)
  • Table 46. Argentina Monoclonal Antibodies, by Source USD Million (2015-2020)
  • Table 47. Argentina Monoclonal Antibodies, by End User USD Million (2015-2020)
  • Table 48. Rest of South America Monoclonal Antibodies, by Application USD Million (2015-2020)
  • Table 49. Rest of South America Monoclonal Antibodies, by Drug Type USD Million (2015-2020)
  • Table 50. Rest of South America Monoclonal Antibodies, by Productions USD Million (2015-2020)
  • Table 51. Rest of South America Monoclonal Antibodies, by Formulation USD Million (2015-2020)
  • Table 52. Rest of South America Monoclonal Antibodies, by Source USD Million (2015-2020)
  • Table 53. Rest of South America Monoclonal Antibodies, by End User USD Million (2015-2020)
  • Table 54. Asia Pacific Monoclonal Antibodies, by Country USD Million (2015-2020)
  • Table 55. Asia Pacific Monoclonal Antibodies, by Application USD Million (2015-2020)
  • Table 56. Asia Pacific Monoclonal Antibodies, by Drug Type USD Million (2015-2020)
  • Table 57. Asia Pacific Monoclonal Antibodies, by Productions USD Million (2015-2020)
  • Table 58. Asia Pacific Monoclonal Antibodies, by Formulation USD Million (2015-2020)
  • Table 59. Asia Pacific Monoclonal Antibodies, by Source USD Million (2015-2020)
  • Table 60. Asia Pacific Monoclonal Antibodies, by End User USD Million (2015-2020)
  • Table 61. China Monoclonal Antibodies, by Application USD Million (2015-2020)
  • Table 62. China Monoclonal Antibodies, by Drug Type USD Million (2015-2020)
  • Table 63. China Monoclonal Antibodies, by Productions USD Million (2015-2020)
  • Table 64. China Monoclonal Antibodies, by Formulation USD Million (2015-2020)
  • Table 65. China Monoclonal Antibodies, by Source USD Million (2015-2020)
  • Table 66. China Monoclonal Antibodies, by End User USD Million (2015-2020)
  • Table 67. Japan Monoclonal Antibodies, by Application USD Million (2015-2020)
  • Table 68. Japan Monoclonal Antibodies, by Drug Type USD Million (2015-2020)
  • Table 69. Japan Monoclonal Antibodies, by Productions USD Million (2015-2020)
  • Table 70. Japan Monoclonal Antibodies, by Formulation USD Million (2015-2020)
  • Table 71. Japan Monoclonal Antibodies, by Source USD Million (2015-2020)
  • Table 72. Japan Monoclonal Antibodies, by End User USD Million (2015-2020)
  • Table 73. India Monoclonal Antibodies, by Application USD Million (2015-2020)
  • Table 74. India Monoclonal Antibodies, by Drug Type USD Million (2015-2020)
  • Table 75. India Monoclonal Antibodies, by Productions USD Million (2015-2020)
  • Table 76. India Monoclonal Antibodies, by Formulation USD Million (2015-2020)
  • Table 77. India Monoclonal Antibodies, by Source USD Million (2015-2020)
  • Table 78. India Monoclonal Antibodies, by End User USD Million (2015-2020)
  • Table 79. South Korea Monoclonal Antibodies, by Application USD Million (2015-2020)
  • Table 80. South Korea Monoclonal Antibodies, by Drug Type USD Million (2015-2020)
  • Table 81. South Korea Monoclonal Antibodies, by Productions USD Million (2015-2020)
  • Table 82. South Korea Monoclonal Antibodies, by Formulation USD Million (2015-2020)
  • Table 83. South Korea Monoclonal Antibodies, by Source USD Million (2015-2020)
  • Table 84. South Korea Monoclonal Antibodies, by End User USD Million (2015-2020)
  • Table 85. Taiwan Monoclonal Antibodies, by Application USD Million (2015-2020)
  • Table 86. Taiwan Monoclonal Antibodies, by Drug Type USD Million (2015-2020)
  • Table 87. Taiwan Monoclonal Antibodies, by Productions USD Million (2015-2020)
  • Table 88. Taiwan Monoclonal Antibodies, by Formulation USD Million (2015-2020)
  • Table 89. Taiwan Monoclonal Antibodies, by Source USD Million (2015-2020)
  • Table 90. Taiwan Monoclonal Antibodies, by End User USD Million (2015-2020)
  • Table 91. Australia Monoclonal Antibodies, by Application USD Million (2015-2020)
  • Table 92. Australia Monoclonal Antibodies, by Drug Type USD Million (2015-2020)
  • Table 93. Australia Monoclonal Antibodies, by Productions USD Million (2015-2020)
  • Table 94. Australia Monoclonal Antibodies, by Formulation USD Million (2015-2020)
  • Table 95. Australia Monoclonal Antibodies, by Source USD Million (2015-2020)
  • Table 96. Australia Monoclonal Antibodies, by End User USD Million (2015-2020)
  • Table 97. Rest of Asia-Pacific Monoclonal Antibodies, by Application USD Million (2015-2020)
  • Table 98. Rest of Asia-Pacific Monoclonal Antibodies, by Drug Type USD Million (2015-2020)
  • Table 99. Rest of Asia-Pacific Monoclonal Antibodies, by Productions USD Million (2015-2020)
  • Table 100. Rest of Asia-Pacific Monoclonal Antibodies, by Formulation USD Million (2015-2020)
  • Table 101. Rest of Asia-Pacific Monoclonal Antibodies, by Source USD Million (2015-2020)
  • Table 102. Rest of Asia-Pacific Monoclonal Antibodies, by End User USD Million (2015-2020)
  • Table 103. Europe Monoclonal Antibodies, by Country USD Million (2015-2020)
  • Table 104. Europe Monoclonal Antibodies, by Application USD Million (2015-2020)
  • Table 105. Europe Monoclonal Antibodies, by Drug Type USD Million (2015-2020)
  • Table 106. Europe Monoclonal Antibodies, by Productions USD Million (2015-2020)
  • Table 107. Europe Monoclonal Antibodies, by Formulation USD Million (2015-2020)
  • Table 108. Europe Monoclonal Antibodies, by Source USD Million (2015-2020)
  • Table 109. Europe Monoclonal Antibodies, by End User USD Million (2015-2020)
  • Table 110. Germany Monoclonal Antibodies, by Application USD Million (2015-2020)
  • Table 111. Germany Monoclonal Antibodies, by Drug Type USD Million (2015-2020)
  • Table 112. Germany Monoclonal Antibodies, by Productions USD Million (2015-2020)
  • Table 113. Germany Monoclonal Antibodies, by Formulation USD Million (2015-2020)
  • Table 114. Germany Monoclonal Antibodies, by Source USD Million (2015-2020)
  • Table 115. Germany Monoclonal Antibodies, by End User USD Million (2015-2020)
  • Table 116. France Monoclonal Antibodies, by Application USD Million (2015-2020)
  • Table 117. France Monoclonal Antibodies, by Drug Type USD Million (2015-2020)
  • Table 118. France Monoclonal Antibodies, by Productions USD Million (2015-2020)
  • Table 119. France Monoclonal Antibodies, by Formulation USD Million (2015-2020)
  • Table 120. France Monoclonal Antibodies, by Source USD Million (2015-2020)
  • Table 121. France Monoclonal Antibodies, by End User USD Million (2015-2020)
  • Table 122. Italy Monoclonal Antibodies, by Application USD Million (2015-2020)
  • Table 123. Italy Monoclonal Antibodies, by Drug Type USD Million (2015-2020)
  • Table 124. Italy Monoclonal Antibodies, by Productions USD Million (2015-2020)
  • Table 125. Italy Monoclonal Antibodies, by Formulation USD Million (2015-2020)
  • Table 126. Italy Monoclonal Antibodies, by Source USD Million (2015-2020)
  • Table 127. Italy Monoclonal Antibodies, by End User USD Million (2015-2020)
  • Table 128. United Kingdom Monoclonal Antibodies, by Application USD Million (2015-2020)
  • Table 129. United Kingdom Monoclonal Antibodies, by Drug Type USD Million (2015-2020)
  • Table 130. United Kingdom Monoclonal Antibodies, by Productions USD Million (2015-2020)
  • Table 131. United Kingdom Monoclonal Antibodies, by Formulation USD Million (2015-2020)
  • Table 132. United Kingdom Monoclonal Antibodies, by Source USD Million (2015-2020)
  • Table 133. United Kingdom Monoclonal Antibodies, by End User USD Million (2015-2020)
  • Table 134. Netherlands Monoclonal Antibodies, by Application USD Million (2015-2020)
  • Table 135. Netherlands Monoclonal Antibodies, by Drug Type USD Million (2015-2020)
  • Table 136. Netherlands Monoclonal Antibodies, by Productions USD Million (2015-2020)
  • Table 137. Netherlands Monoclonal Antibodies, by Formulation USD Million (2015-2020)
  • Table 138. Netherlands Monoclonal Antibodies, by Source USD Million (2015-2020)
  • Table 139. Netherlands Monoclonal Antibodies, by End User USD Million (2015-2020)
  • Table 140. Rest of Europe Monoclonal Antibodies, by Application USD Million (2015-2020)
  • Table 141. Rest of Europe Monoclonal Antibodies, by Drug Type USD Million (2015-2020)
  • Table 142. Rest of Europe Monoclonal Antibodies, by Productions USD Million (2015-2020)
  • Table 143. Rest of Europe Monoclonal Antibodies, by Formulation USD Million (2015-2020)
  • Table 144. Rest of Europe Monoclonal Antibodies, by Source USD Million (2015-2020)
  • Table 145. Rest of Europe Monoclonal Antibodies, by End User USD Million (2015-2020)
  • Table 146. MEA Monoclonal Antibodies, by Country USD Million (2015-2020)
  • Table 147. MEA Monoclonal Antibodies, by Application USD Million (2015-2020)
  • Table 148. MEA Monoclonal Antibodies, by Drug Type USD Million (2015-2020)
  • Table 149. MEA Monoclonal Antibodies, by Productions USD Million (2015-2020)
  • Table 150. MEA Monoclonal Antibodies, by Formulation USD Million (2015-2020)
  • Table 151. MEA Monoclonal Antibodies, by Source USD Million (2015-2020)
  • Table 152. MEA Monoclonal Antibodies, by End User USD Million (2015-2020)
  • Table 153. Middle East Monoclonal Antibodies, by Application USD Million (2015-2020)
  • Table 154. Middle East Monoclonal Antibodies, by Drug Type USD Million (2015-2020)
  • Table 155. Middle East Monoclonal Antibodies, by Productions USD Million (2015-2020)
  • Table 156. Middle East Monoclonal Antibodies, by Formulation USD Million (2015-2020)
  • Table 157. Middle East Monoclonal Antibodies, by Source USD Million (2015-2020)
  • Table 158. Middle East Monoclonal Antibodies, by End User USD Million (2015-2020)
  • Table 159. Africa Monoclonal Antibodies, by Application USD Million (2015-2020)
  • Table 160. Africa Monoclonal Antibodies, by Drug Type USD Million (2015-2020)
  • Table 161. Africa Monoclonal Antibodies, by Productions USD Million (2015-2020)
  • Table 162. Africa Monoclonal Antibodies, by Formulation USD Million (2015-2020)
  • Table 163. Africa Monoclonal Antibodies, by Source USD Million (2015-2020)
  • Table 164. Africa Monoclonal Antibodies, by End User USD Million (2015-2020)
  • Table 165. North America Monoclonal Antibodies, by Country USD Million (2015-2020)
  • Table 166. North America Monoclonal Antibodies, by Application USD Million (2015-2020)
  • Table 167. North America Monoclonal Antibodies, by Drug Type USD Million (2015-2020)
  • Table 168. North America Monoclonal Antibodies, by Productions USD Million (2015-2020)
  • Table 169. North America Monoclonal Antibodies, by Formulation USD Million (2015-2020)
  • Table 170. North America Monoclonal Antibodies, by Source USD Million (2015-2020)
  • Table 171. North America Monoclonal Antibodies, by End User USD Million (2015-2020)
  • Table 172. United States Monoclonal Antibodies, by Application USD Million (2015-2020)
  • Table 173. United States Monoclonal Antibodies, by Drug Type USD Million (2015-2020)
  • Table 174. United States Monoclonal Antibodies, by Productions USD Million (2015-2020)
  • Table 175. United States Monoclonal Antibodies, by Formulation USD Million (2015-2020)
  • Table 176. United States Monoclonal Antibodies, by Source USD Million (2015-2020)
  • Table 177. United States Monoclonal Antibodies, by End User USD Million (2015-2020)
  • Table 178. Canada Monoclonal Antibodies, by Application USD Million (2015-2020)
  • Table 179. Canada Monoclonal Antibodies, by Drug Type USD Million (2015-2020)
  • Table 180. Canada Monoclonal Antibodies, by Productions USD Million (2015-2020)
  • Table 181. Canada Monoclonal Antibodies, by Formulation USD Million (2015-2020)
  • Table 182. Canada Monoclonal Antibodies, by Source USD Million (2015-2020)
  • Table 183. Canada Monoclonal Antibodies, by End User USD Million (2015-2020)
  • Table 184. Mexico Monoclonal Antibodies, by Application USD Million (2015-2020)
  • Table 185. Mexico Monoclonal Antibodies, by Drug Type USD Million (2015-2020)
  • Table 186. Mexico Monoclonal Antibodies, by Productions USD Million (2015-2020)
  • Table 187. Mexico Monoclonal Antibodies, by Formulation USD Million (2015-2020)
  • Table 188. Mexico Monoclonal Antibodies, by Source USD Million (2015-2020)
  • Table 189. Mexico Monoclonal Antibodies, by End User USD Million (2015-2020)
  • Table 190. Company Basic Information, Sales Area and Its Competitors
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Monoclonal Antibodies: by Application(USD Million)
  • Table 201. Monoclonal Antibodies Cancer , by Region USD Million (2021-2026)
  • Table 202. Monoclonal Antibodies Rheumatoid arthritis , by Region USD Million (2021-2026)
  • Table 203. Monoclonal Antibodies Multiple sclerosis , by Region USD Million (2021-2026)
  • Table 204. Monoclonal Antibodies Cardiovascular disease , by Region USD Million (2021-2026)
  • Table 205. Monoclonal Antibodies Systemic lupus erythematosus , by Region USD Million (2021-2026)
  • Table 206. Monoclonal Antibodies Crohn's disease , by Region USD Million (2021-2026)
  • Table 207. Monoclonal Antibodies Other , by Region USD Million (2021-2026)
  • Table 208. Monoclonal Antibodies: by Drug Type(USD Million)
  • Table 209. Monoclonal Antibodies Abciximab , by Region USD Million (2021-2026)
  • Table 210. Monoclonal Antibodies Adalimumab , by Region USD Million (2021-2026)
  • Table 211. Monoclonal Antibodies Alefacept , by Region USD Million (2021-2026)
  • Table 212. Monoclonal Antibodies Other , by Region USD Million (2021-2026)
  • Table 213. Monoclonal Antibodies: by Productions(USD Million)
  • Table 214. Monoclonal Antibodies Vivo , by Region USD Million (2021-2026)
  • Table 215. Monoclonal Antibodies Vitro , by Region USD Million (2021-2026)
  • Table 216. Monoclonal Antibodies: by Formulation(USD Million)
  • Table 217. Monoclonal Antibodies Lyophilized powder for reconstitution , by Region USD Million (2021-2026)
  • Table 218. Monoclonal Antibodies Solution for injection , by Region USD Million (2021-2026)
  • Table 219. Monoclonal Antibodies: by Source(USD Million)
  • Table 220. Monoclonal Antibodies Fully human , by Region USD Million (2021-2026)
  • Table 221. Monoclonal Antibodies Humanized , by Region USD Million (2021-2026)
  • Table 222. Monoclonal Antibodies Chimeric , by Region USD Million (2021-2026)
  • Table 223. Monoclonal Antibodies Other , by Region USD Million (2021-2026)
  • Table 224. Monoclonal Antibodies: by End User(USD Million)
  • Table 225. Monoclonal Antibodies Hospitals , by Region USD Million (2021-2026)
  • Table 226. Monoclonal Antibodies Speciality centers , by Region USD Million (2021-2026)
  • Table 227. Monoclonal Antibodies Others , by Region USD Million (2021-2026)
  • Table 228. South America Monoclonal Antibodies, by Country USD Million (2021-2026)
  • Table 229. South America Monoclonal Antibodies, by Application USD Million (2021-2026)
  • Table 230. South America Monoclonal Antibodies, by Drug Type USD Million (2021-2026)
  • Table 231. South America Monoclonal Antibodies, by Productions USD Million (2021-2026)
  • Table 232. South America Monoclonal Antibodies, by Formulation USD Million (2021-2026)
  • Table 233. South America Monoclonal Antibodies, by Source USD Million (2021-2026)
  • Table 234. South America Monoclonal Antibodies, by End User USD Million (2021-2026)
  • Table 235. Brazil Monoclonal Antibodies, by Application USD Million (2021-2026)
  • Table 236. Brazil Monoclonal Antibodies, by Drug Type USD Million (2021-2026)
  • Table 237. Brazil Monoclonal Antibodies, by Productions USD Million (2021-2026)
  • Table 238. Brazil Monoclonal Antibodies, by Formulation USD Million (2021-2026)
  • Table 239. Brazil Monoclonal Antibodies, by Source USD Million (2021-2026)
  • Table 240. Brazil Monoclonal Antibodies, by End User USD Million (2021-2026)
  • Table 241. Argentina Monoclonal Antibodies, by Application USD Million (2021-2026)
  • Table 242. Argentina Monoclonal Antibodies, by Drug Type USD Million (2021-2026)
  • Table 243. Argentina Monoclonal Antibodies, by Productions USD Million (2021-2026)
  • Table 244. Argentina Monoclonal Antibodies, by Formulation USD Million (2021-2026)
  • Table 245. Argentina Monoclonal Antibodies, by Source USD Million (2021-2026)
  • Table 246. Argentina Monoclonal Antibodies, by End User USD Million (2021-2026)
  • Table 247. Rest of South America Monoclonal Antibodies, by Application USD Million (2021-2026)
  • Table 248. Rest of South America Monoclonal Antibodies, by Drug Type USD Million (2021-2026)
  • Table 249. Rest of South America Monoclonal Antibodies, by Productions USD Million (2021-2026)
  • Table 250. Rest of South America Monoclonal Antibodies, by Formulation USD Million (2021-2026)
  • Table 251. Rest of South America Monoclonal Antibodies, by Source USD Million (2021-2026)
  • Table 252. Rest of South America Monoclonal Antibodies, by End User USD Million (2021-2026)
  • Table 253. Asia Pacific Monoclonal Antibodies, by Country USD Million (2021-2026)
  • Table 254. Asia Pacific Monoclonal Antibodies, by Application USD Million (2021-2026)
  • Table 255. Asia Pacific Monoclonal Antibodies, by Drug Type USD Million (2021-2026)
  • Table 256. Asia Pacific Monoclonal Antibodies, by Productions USD Million (2021-2026)
  • Table 257. Asia Pacific Monoclonal Antibodies, by Formulation USD Million (2021-2026)
  • Table 258. Asia Pacific Monoclonal Antibodies, by Source USD Million (2021-2026)
  • Table 259. Asia Pacific Monoclonal Antibodies, by End User USD Million (2021-2026)
  • Table 260. China Monoclonal Antibodies, by Application USD Million (2021-2026)
  • Table 261. China Monoclonal Antibodies, by Drug Type USD Million (2021-2026)
  • Table 262. China Monoclonal Antibodies, by Productions USD Million (2021-2026)
  • Table 263. China Monoclonal Antibodies, by Formulation USD Million (2021-2026)
  • Table 264. China Monoclonal Antibodies, by Source USD Million (2021-2026)
  • Table 265. China Monoclonal Antibodies, by End User USD Million (2021-2026)
  • Table 266. Japan Monoclonal Antibodies, by Application USD Million (2021-2026)
  • Table 267. Japan Monoclonal Antibodies, by Drug Type USD Million (2021-2026)
  • Table 268. Japan Monoclonal Antibodies, by Productions USD Million (2021-2026)
  • Table 269. Japan Monoclonal Antibodies, by Formulation USD Million (2021-2026)
  • Table 270. Japan Monoclonal Antibodies, by Source USD Million (2021-2026)
  • Table 271. Japan Monoclonal Antibodies, by End User USD Million (2021-2026)
  • Table 272. India Monoclonal Antibodies, by Application USD Million (2021-2026)
  • Table 273. India Monoclonal Antibodies, by Drug Type USD Million (2021-2026)
  • Table 274. India Monoclonal Antibodies, by Productions USD Million (2021-2026)
  • Table 275. India Monoclonal Antibodies, by Formulation USD Million (2021-2026)
  • Table 276. India Monoclonal Antibodies, by Source USD Million (2021-2026)
  • Table 277. India Monoclonal Antibodies, by End User USD Million (2021-2026)
  • Table 278. South Korea Monoclonal Antibodies, by Application USD Million (2021-2026)
  • Table 279. South Korea Monoclonal Antibodies, by Drug Type USD Million (2021-2026)
  • Table 280. South Korea Monoclonal Antibodies, by Productions USD Million (2021-2026)
  • Table 281. South Korea Monoclonal Antibodies, by Formulation USD Million (2021-2026)
  • Table 282. South Korea Monoclonal Antibodies, by Source USD Million (2021-2026)
  • Table 283. South Korea Monoclonal Antibodies, by End User USD Million (2021-2026)
  • Table 284. Taiwan Monoclonal Antibodies, by Application USD Million (2021-2026)
  • Table 285. Taiwan Monoclonal Antibodies, by Drug Type USD Million (2021-2026)
  • Table 286. Taiwan Monoclonal Antibodies, by Productions USD Million (2021-2026)
  • Table 287. Taiwan Monoclonal Antibodies, by Formulation USD Million (2021-2026)
  • Table 288. Taiwan Monoclonal Antibodies, by Source USD Million (2021-2026)
  • Table 289. Taiwan Monoclonal Antibodies, by End User USD Million (2021-2026)
  • Table 290. Australia Monoclonal Antibodies, by Application USD Million (2021-2026)
  • Table 291. Australia Monoclonal Antibodies, by Drug Type USD Million (2021-2026)
  • Table 292. Australia Monoclonal Antibodies, by Productions USD Million (2021-2026)
  • Table 293. Australia Monoclonal Antibodies, by Formulation USD Million (2021-2026)
  • Table 294. Australia Monoclonal Antibodies, by Source USD Million (2021-2026)
  • Table 295. Australia Monoclonal Antibodies, by End User USD Million (2021-2026)
  • Table 296. Rest of Asia-Pacific Monoclonal Antibodies, by Application USD Million (2021-2026)
  • Table 297. Rest of Asia-Pacific Monoclonal Antibodies, by Drug Type USD Million (2021-2026)
  • Table 298. Rest of Asia-Pacific Monoclonal Antibodies, by Productions USD Million (2021-2026)
  • Table 299. Rest of Asia-Pacific Monoclonal Antibodies, by Formulation USD Million (2021-2026)
  • Table 300. Rest of Asia-Pacific Monoclonal Antibodies, by Source USD Million (2021-2026)
  • Table 301. Rest of Asia-Pacific Monoclonal Antibodies, by End User USD Million (2021-2026)
  • Table 302. Europe Monoclonal Antibodies, by Country USD Million (2021-2026)
  • Table 303. Europe Monoclonal Antibodies, by Application USD Million (2021-2026)
  • Table 304. Europe Monoclonal Antibodies, by Drug Type USD Million (2021-2026)
  • Table 305. Europe Monoclonal Antibodies, by Productions USD Million (2021-2026)
  • Table 306. Europe Monoclonal Antibodies, by Formulation USD Million (2021-2026)
  • Table 307. Europe Monoclonal Antibodies, by Source USD Million (2021-2026)
  • Table 308. Europe Monoclonal Antibodies, by End User USD Million (2021-2026)
  • Table 309. Germany Monoclonal Antibodies, by Application USD Million (2021-2026)
  • Table 310. Germany Monoclonal Antibodies, by Drug Type USD Million (2021-2026)
  • Table 311. Germany Monoclonal Antibodies, by Productions USD Million (2021-2026)
  • Table 312. Germany Monoclonal Antibodies, by Formulation USD Million (2021-2026)
  • Table 313. Germany Monoclonal Antibodies, by Source USD Million (2021-2026)
  • Table 314. Germany Monoclonal Antibodies, by End User USD Million (2021-2026)
  • Table 315. France Monoclonal Antibodies, by Application USD Million (2021-2026)
  • Table 316. France Monoclonal Antibodies, by Drug Type USD Million (2021-2026)
  • Table 317. France Monoclonal Antibodies, by Productions USD Million (2021-2026)
  • Table 318. France Monoclonal Antibodies, by Formulation USD Million (2021-2026)
  • Table 319. France Monoclonal Antibodies, by Source USD Million (2021-2026)
  • Table 320. France Monoclonal Antibodies, by End User USD Million (2021-2026)
  • Table 321. Italy Monoclonal Antibodies, by Application USD Million (2021-2026)
  • Table 322. Italy Monoclonal Antibodies, by Drug Type USD Million (2021-2026)
  • Table 323. Italy Monoclonal Antibodies, by Productions USD Million (2021-2026)
  • Table 324. Italy Monoclonal Antibodies, by Formulation USD Million (2021-2026)
  • Table 325. Italy Monoclonal Antibodies, by Source USD Million (2021-2026)
  • Table 326. Italy Monoclonal Antibodies, by End User USD Million (2021-2026)
  • Table 327. United Kingdom Monoclonal Antibodies, by Application USD Million (2021-2026)
  • Table 328. United Kingdom Monoclonal Antibodies, by Drug Type USD Million (2021-2026)
  • Table 329. United Kingdom Monoclonal Antibodies, by Productions USD Million (2021-2026)
  • Table 330. United Kingdom Monoclonal Antibodies, by Formulation USD Million (2021-2026)
  • Table 331. United Kingdom Monoclonal Antibodies, by Source USD Million (2021-2026)
  • Table 332. United Kingdom Monoclonal Antibodies, by End User USD Million (2021-2026)
  • Table 333. Netherlands Monoclonal Antibodies, by Application USD Million (2021-2026)
  • Table 334. Netherlands Monoclonal Antibodies, by Drug Type USD Million (2021-2026)
  • Table 335. Netherlands Monoclonal Antibodies, by Productions USD Million (2021-2026)
  • Table 336. Netherlands Monoclonal Antibodies, by Formulation USD Million (2021-2026)
  • Table 337. Netherlands Monoclonal Antibodies, by Source USD Million (2021-2026)
  • Table 338. Netherlands Monoclonal Antibodies, by End User USD Million (2021-2026)
  • Table 339. Rest of Europe Monoclonal Antibodies, by Application USD Million (2021-2026)
  • Table 340. Rest of Europe Monoclonal Antibodies, by Drug Type USD Million (2021-2026)
  • Table 341. Rest of Europe Monoclonal Antibodies, by Productions USD Million (2021-2026)
  • Table 342. Rest of Europe Monoclonal Antibodies, by Formulation USD Million (2021-2026)
  • Table 343. Rest of Europe Monoclonal Antibodies, by Source USD Million (2021-2026)
  • Table 344. Rest of Europe Monoclonal Antibodies, by End User USD Million (2021-2026)
  • Table 345. MEA Monoclonal Antibodies, by Country USD Million (2021-2026)
  • Table 346. MEA Monoclonal Antibodies, by Application USD Million (2021-2026)
  • Table 347. MEA Monoclonal Antibodies, by Drug Type USD Million (2021-2026)
  • Table 348. MEA Monoclonal Antibodies, by Productions USD Million (2021-2026)
  • Table 349. MEA Monoclonal Antibodies, by Formulation USD Million (2021-2026)
  • Table 350. MEA Monoclonal Antibodies, by Source USD Million (2021-2026)
  • Table 351. MEA Monoclonal Antibodies, by End User USD Million (2021-2026)
  • Table 352. Middle East Monoclonal Antibodies, by Application USD Million (2021-2026)
  • Table 353. Middle East Monoclonal Antibodies, by Drug Type USD Million (2021-2026)
  • Table 354. Middle East Monoclonal Antibodies, by Productions USD Million (2021-2026)
  • Table 355. Middle East Monoclonal Antibodies, by Formulation USD Million (2021-2026)
  • Table 356. Middle East Monoclonal Antibodies, by Source USD Million (2021-2026)
  • Table 357. Middle East Monoclonal Antibodies, by End User USD Million (2021-2026)
  • Table 358. Africa Monoclonal Antibodies, by Application USD Million (2021-2026)
  • Table 359. Africa Monoclonal Antibodies, by Drug Type USD Million (2021-2026)
  • Table 360. Africa Monoclonal Antibodies, by Productions USD Million (2021-2026)
  • Table 361. Africa Monoclonal Antibodies, by Formulation USD Million (2021-2026)
  • Table 362. Africa Monoclonal Antibodies, by Source USD Million (2021-2026)
  • Table 363. Africa Monoclonal Antibodies, by End User USD Million (2021-2026)
  • Table 364. North America Monoclonal Antibodies, by Country USD Million (2021-2026)
  • Table 365. North America Monoclonal Antibodies, by Application USD Million (2021-2026)
  • Table 366. North America Monoclonal Antibodies, by Drug Type USD Million (2021-2026)
  • Table 367. North America Monoclonal Antibodies, by Productions USD Million (2021-2026)
  • Table 368. North America Monoclonal Antibodies, by Formulation USD Million (2021-2026)
  • Table 369. North America Monoclonal Antibodies, by Source USD Million (2021-2026)
  • Table 370. North America Monoclonal Antibodies, by End User USD Million (2021-2026)
  • Table 371. United States Monoclonal Antibodies, by Application USD Million (2021-2026)
  • Table 372. United States Monoclonal Antibodies, by Drug Type USD Million (2021-2026)
  • Table 373. United States Monoclonal Antibodies, by Productions USD Million (2021-2026)
  • Table 374. United States Monoclonal Antibodies, by Formulation USD Million (2021-2026)
  • Table 375. United States Monoclonal Antibodies, by Source USD Million (2021-2026)
  • Table 376. United States Monoclonal Antibodies, by End User USD Million (2021-2026)
  • Table 377. Canada Monoclonal Antibodies, by Application USD Million (2021-2026)
  • Table 378. Canada Monoclonal Antibodies, by Drug Type USD Million (2021-2026)
  • Table 379. Canada Monoclonal Antibodies, by Productions USD Million (2021-2026)
  • Table 380. Canada Monoclonal Antibodies, by Formulation USD Million (2021-2026)
  • Table 381. Canada Monoclonal Antibodies, by Source USD Million (2021-2026)
  • Table 382. Canada Monoclonal Antibodies, by End User USD Million (2021-2026)
  • Table 383. Mexico Monoclonal Antibodies, by Application USD Million (2021-2026)
  • Table 384. Mexico Monoclonal Antibodies, by Drug Type USD Million (2021-2026)
  • Table 385. Mexico Monoclonal Antibodies, by Productions USD Million (2021-2026)
  • Table 386. Mexico Monoclonal Antibodies, by Formulation USD Million (2021-2026)
  • Table 387. Mexico Monoclonal Antibodies, by Source USD Million (2021-2026)
  • Table 388. Mexico Monoclonal Antibodies, by End User USD Million (2021-2026)
  • Table 389. Research Programs/Design for This Report
  • Table 390. Key Data Information from Secondary Sources
  • Table 391. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Monoclonal Antibodies: by Application USD Million (2015-2020)
  • Figure 5. Global Monoclonal Antibodies: by Drug Type USD Million (2015-2020)
  • Figure 6. Global Monoclonal Antibodies: by Productions USD Million (2015-2020)
  • Figure 7. Global Monoclonal Antibodies: by Formulation USD Million (2015-2020)
  • Figure 8. Global Monoclonal Antibodies: by Source USD Million (2015-2020)
  • Figure 9. Global Monoclonal Antibodies: by End User USD Million (2015-2020)
  • Figure 10. South America Monoclonal Antibodies Share (%), by Country
  • Figure 11. Asia Pacific Monoclonal Antibodies Share (%), by Country
  • Figure 12. Europe Monoclonal Antibodies Share (%), by Country
  • Figure 13. MEA Monoclonal Antibodies Share (%), by Country
  • Figure 14. North America Monoclonal Antibodies Share (%), by Country
  • Figure 15. Global Monoclonal Antibodies share by Players 2020 (%)
  • Figure 16. Global Monoclonal Antibodies share by Players (Top 3) 2020(%)
  • Figure 17. Global Monoclonal Antibodies share by Players (Top 5) 2020(%)
  • Figure 18. BCG Matrix for key Companies
  • Figure 19. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 20. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 21. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Pfizer, Inc. (United States) Revenue: by Geography 2020
  • Figure 23. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 24. AstraZeneca (United Kingdom) Revenue: by Geography 2020
  • Figure 25. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 26. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2020
  • Figure 27. Johnson & Johnson Services, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Johnson & Johnson Services, Inc. (United States) Revenue: by Geography 2020
  • Figure 29. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 30. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2020
  • Figure 31. Amgen, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Amgen, Inc. (United States) Revenue: by Geography 2020
  • Figure 33. Merck & Co., Inc (United States) Revenue, Net Income and Gross profit
  • Figure 34. Merck & Co., Inc (United States) Revenue: by Geography 2020
  • Figure 35. Daiichi Sankyo Company, Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 36. Daiichi Sankyo Company, Ltd. (Japan) Revenue: by Geography 2020
  • Figure 37. Novo Nordisk A/S (Denmark) Revenue, Net Income and Gross profit
  • Figure 38. Novo Nordisk A/S (Denmark) Revenue: by Geography 2020
  • Figure 39. Global Monoclonal Antibodies: by Application USD Million (2021-2026)
  • Figure 40. Global Monoclonal Antibodies: by Drug Type USD Million (2021-2026)
  • Figure 41. Global Monoclonal Antibodies: by Productions USD Million (2021-2026)
  • Figure 42. Global Monoclonal Antibodies: by Formulation USD Million (2021-2026)
  • Figure 43. Global Monoclonal Antibodies: by Source USD Million (2021-2026)
  • Figure 44. Global Monoclonal Antibodies: by End User USD Million (2021-2026)
  • Figure 45. South America Monoclonal Antibodies Share (%), by Country
  • Figure 46. Asia Pacific Monoclonal Antibodies Share (%), by Country
  • Figure 47. Europe Monoclonal Antibodies Share (%), by Country
  • Figure 48. MEA Monoclonal Antibodies Share (%), by Country
  • Figure 49. North America Monoclonal Antibodies Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Novartis AG (Switzerland)
  • Pfizer, Inc. (United States)
  • AstraZeneca (United Kingdom)
  • GlaxoSmithKline plc (United Kingdom)
  • Johnson & Johnson Services, Inc. (United States)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Amgen, Inc. (United States)
  • Merck & Co., Inc (United States)
  • Daiichi Sankyo Company, Ltd. (Japan)
  • Novo Nordisk A/S (Denmark)
Additional players considered in the study are as follows:
Abbott (United States) , Eli Lilly (United States) , Bayer AG (United States) , Bristol Myers Squibb Co. (United States) , Mylan N.V. (United States) , Biogen Inc. (United States) , Thermo Fisher Scientific, Inc. (United States) , Sanofi Genzyme (France)
Select User Access Type

Key Highlights of Report


Jul 2022 215 Pages 62 Tables Base Year: 2020 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Monoclonal Antibodies Quantitative research analysis
Global Monoclonal Antibodies Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Monoclonal Antibodies study can be customized to meet your requirements. The market size breakdown by end use application [Cancer, Rheumatoid arthritis, Multiple sclerosis, Cardiovascular disease, Systemic lupus erythematosus, Crohn's disease and Other].
The Monoclonal Antibodies Market is gaining popularity and expected to see strong valuation by 2026.
  • The Monoclonal Antibodies Therapy Use in Cancer Treatment Has Been Driving the Market Growth.

Know More About Global Monoclonal Antibodies Report?

Have a Query? Click Here

Other Related Reports

Horseradish Peroxidase Comprehensive Study by Type (Grade I, Grade II, Grade III), Application (Biotechnology, Pharmaceutical Companies, Research Institutes, Other), Sales Channel (Direct, Indirect) ...
$ 3500
Anatomic Pathology Comprehensive Study by Type (Instruments (Tissue Processors, Microtome, Cryostats, Others), Consumables (Reagents(Stains & Dyes,Fixatives,Others), Antibodies), Histopathology), App...
$ 3650
Medical Polymers Comprehensive Study by Type (Medical Fibers & Resins (Polyvinyl chloride (PVC), Polypropylene (PP), Polyethylene (PE), Polystyrene (PS), others), Medical Elastomers (Styrene Block Co...
$ 3750
Nano Biosensors - Comprehensive Study by Application (Biological Application {DNA Sensors, Immunosensors, Cell based Sensor, Point of care Sensors, bacteria sensors, others}, Environmental Applicatio...
$ 4000
Bioresorbable Polymers Comprehensive Study by Type (Polylactic acid, Polyglycolic acid, Polycaprolactone, Polysaccharides, Proteins, Others), Application (Drug Delivery, Orthopedics, Others), Origin ...
$ 3450
Marine Enzymes Comprehensive Study by Type (Amylases, Lipases, DNases, Other), Application (Food and Beverages, Pharmaceutical, Neutraceutical, Cosmetic Industry, Other), Source (Microorganisms {Extr...
$ 3500